Clinically, CDH3 correlated with cancer‐related signatures and was overexpressed in a subset of patients with poor prognosis, thus suggesting that CDH3 could hold a prognostic value for patients with GBM (Scheme drawn with images from Servier Medical Art; https://smart.servier.com/). This evidence concerns the gene CDH3 and cancer.